CPC A61K 31/19 (2013.01) [A23L 33/12 (2016.08); A23L 33/16 (2016.08); A23L 33/175 (2016.08); A61K 9/006 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/0095 (2013.01); A61K 9/02 (2013.01); A61K 9/14 (2013.01); A61K 9/145 (2013.01); A61K 9/2004 (2013.01); A61K 9/2013 (2013.01); A61K 9/4841 (2013.01); A61K 9/4858 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61P 3/00 (2018.01); A23V 2002/00 (2013.01); A23V 2200/30 (2013.01); A23V 2250/02 (2013.01); A23V 2250/1876 (2013.01); A23V 2250/1878 (2013.01); A23V 2250/1884 (2013.01)] | 23 Claims |
1. A composition for increasing ketone level in a subject, comprising:
a plurality of beta-hydroxybutyrate salts comprised of:
at least one beta-hydroxybutyrate salt selected from:
calcium beta-hydroxybutyrate; and
magnesium beta-hydroxybutyrate; and
at least one other beta-hydroxybutyrate salt selected from:
sodium beta-hydroxybutyrate;
potassium beta-hydroxybutyrate;
calcium beta-hydroxybutyrate; and
magnesium beta-hydroxybutyrate; and
at least one additional ketone body or ketone precursor selected from the group consisting of acetoacetate, ketone ester, amino acid salt of beta-hydroxybutyrate, and other ketone body or ketone precursor that causes a rise in blood ketone level without adding more electrolytes to the subject's bloodstream,
wherein the composition is free of medium chain fatty acids having 6 to 12 carbons and glycerides or other esters thereof.
|